Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial

Thierry Troosters1, Frank C Sciurba2, Marc Decramer3, Nikos M Siafakas4, Solomon S Klioze5,7, Santosh C Sutradhar6, Idelle M Weisman6 and Carla Yunis6

BACKGROUND: The benefits of pharmacotherapy with tiotropium HandiHaler 18 μg for patients with chronic obstructive pulmonary disease (COPD) have been previously demonstrated. However, few data exist regarding the treatment of moderate disease (Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage II).

AIMS: To determine whether tiotropium improves lung function/patient-reported outcomes in patients with GOLD stage II COPD naive to maintenance therapy.

METHODS: A randomised 24-week double-blind placebo-controlled trial of tiotropium 18 μg once daily (via HandiHaler) was performed in maintenance therapy–naïve patients with forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio < 0.7 and post-bronchodilator FEV1 ≥ 50 and < 80%.

RESULTS: A total of 457 patients were randomised (238 tiotropium, 219 placebo; mean age 62 years; FEV1 1.93 l (66% predicted)). Tiotropium was superior to placebo in mean change from baseline in post-dose FEV1 area under the curve from 0 to 3 h (AUC0–3h) at week 24 (primary endpoint): 0.19 vs. −0.03 l (least-squares mean difference 0.23 l, P < 0.001). FVC AUC0–3h, trough and peak FEV1 and FVC were significantly improved with tiotropium versus placebo (P < 0.001). Compared with placebo, tiotropium provided numerical improvements in physical activity (P = NS), Physician’s Global Assessment (health status) improved (P = 0.045) with less impairment on the Work Productivity and Activity Impairment questionnaire (P = 0.043) at week 24. The incidence of exacerbations, cough, bronchitis and dyspnoea was lower with tiotropium than placebo.

CONCLUSIONS: Tiotropium improved lung function and patient-reported outcomes in maintenance therapy–naïve patients with GOLD stage II COPD, suggesting benefits in initiating maintenance therapy early.

njp Primary Care Respiratory Medicine (2014) 24, Article number: 14003; doi:10.1038/npjpcrm.2014.3; published online 20 May 2014

INTRODUCTION

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines recommend maintenance therapy for patients with a post-bronchodilator forced expiratory volume in 1 s (FEV1) < 80% of predicted normal and FEV1/forced vital capacity (FVC) ratio of < 0.7.1 However, retrospective studies suggest that maintenance therapy is not typically initiated until individuals experience severe airflow obstruction and significant symptoms.2,3 The benefits of pharmacotherapy for chronic obstructive pulmonary disease (COPD) have been demonstrated in numerous trials,4–6 but few data exist regarding the treatment of moderate (GOLD stage II) disease.

Secondary analyses of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT)7 and TOwards a Revolution in COPD Health (TORCH)8,9 trials suggested that long-acting bronchodilators reduce the rate of decline of FEV1 in GOLD stage II COPD. A secondary analysis of patients in the UPLIFT trial previously untreated with other long-acting bronchodilators or inhaled corticosteroids (ICS) also demonstrated acute and long-term benefits of tiotropium therapy.10 However, many patients received concomitant maintenance therapy (long-acting β2-agonists and/or ICS) during the UPLIFT trial; only 38% of patients receiving tiotropium and 27% of patients receiving placebo were maintenance therapy naïve at baseline, and < 26% of patients overall received no long-acting β2-agonist and/or ICS.2 The long-term impact of tiotropium as the first and only maintenance therapy on lung function in moderate COPD is therefore less clear.

The effects of pharmacological interventions on patient-centred outcomes such as physical activity are largely unknown in moderate COPD. In patients with severe COPD (mean FEV1 43–44% predicted), tiotropium reduces dynamic hyperinflation and dyspnoea, thereby improving exercise tolerance.11–13 When combined with pulmonary rehabilitation (in patients with mean FEV1 34% predicted), tiotropium improved exercise endurance, dyspnoea and health status.11 Whether these benefits translate into enhanced physical activity requires further investigation.

Three studies have investigated physical activity in early COPD;14–16 they did not report concomitant medication status, and patients were recruited from tertiary care. All reported significantly reduced physical activity in these patients. The present trial investigated lung function improvement with tiotropium 18 μg/day administered via HandiHaler as the first and only maintenance therapy in patients with moderate COPD. Furthermore, the effect of tiotropium on physical activity, worker productivity and health status was measured. This study is among the first to use a validated activity monitoring device to assess physical activity during pharmacological intervention in a relatively large COPD population.

1Department of Rehabilitation Sciences and Respiratory Division UZ Leuven, Katholieke Universiteit Leuven, Leuven, Belgium; 2Emphysema Research Center, Division of Pulmonary and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 3Pneumology, Katholieke Universiteit Leuven and University Hospitals Leuven, Leuven, Belgium; 4University Hospital of Heraklion, Heraklion, Greece; 5Pfizer, Groton, CT, USA and 6Pfizer, New York, NY, USA.

Correspondence: T Troosters (thierry.troosters@med.kuleuven.be)

© 2014 Primary Care Respiratory Society UK/Macmillan Publishers Limited
MATERIALS AND METHODS

Study design

The study design (Figure 1) and methods have been reported previously.17 This 24-week randomised parallel-group double-blind placebo-controlled multicentre trial of patients with GOLD stage II COPD previously naive to maintenance therapy was conducted at 70 centres in 10 countries (ClinicalTrials.gov identifier NCT00523991; study number 205.365).

The primary endpoint was the FEV1 area under the curve from 0 to 3 h (AUC0–3h) post-dose response at week 24 (final visit). The objective was to evaluate the difference between treatment with tiotropium 18 μg once daily via HandiHaler plus p.r.n. salbutamol versus placebo once daily via HandiHaler plus p.r.n. salbutamol on the FEV1, AUC0–3h, post-dose response at week 24. Response was defined as change from baseline in pre-dose FEV1 to 3 h post-dose at week 24 (final visit).

Secondary outcome measures included other FEV1 and FVC parameters, physical activity and energy expenditure, physician’s and patient’s global assessments of health status and work productivity.

Safety evaluations included the assessment of adverse events (AEs), serious adverse events (SAEs) and COPD exacerbations.

Patients

Inclusion and exclusion criteria are summarised in Table 1. All patients provided signed informed consent, consistent with the International Conference on Harmonisation—Good Clinical Practice Guidelines18 prior to study participation. Co-morbidities present at baseline were based on self-report and/or analysis of available medical records.

Randomisation and interventions

After screening, patients entered a one-month run-in period. During screening, all patients received single-blinded placebo from week −3 (screening phase) until week 0 (baseline, randomisation). During the active double-blind treatment phase, patients were randomised in a 1:1 ratio to tiotropium bromide 18 μg or placebo once daily via HandiHaler, self-administered in the morning for 24 weeks. Open-label salbutamol p.r.n. was permitted as rescue medication during the screening and treatment periods.

Prohibited medications during the six months before and throughout the study (including screening) were: long-acting β2-agonists; short-acting β2-agonists (except salbutamol after visit 1); oral β2-agonists; ICS; ICS/long-acting β2-agonist combinations; oral corticosteroids; theophylline; leukotriene antagonists; all open-label anticholinergics (including ipratropium, tiotropium, combinations of these and oxicromip). Temporal oral corticosteroids for up to two weeks during the study treatment period were permitted for acute exacerbations.

Procedures and outcome measures

Spirometry was performed at week −4 (screening phase), at week 0 (baseline/randomisation) and at weeks 8, 16 and 24 (end of study) in accordance with American Thoracic Society criteria.19 Physical activity levels were measured using a validated activity monitor, the SenseWear Armband (BodyMedia, Pittsburgh, PA, USA, using software version 6.1).20 Physical activity and energy expenditure (over time, using predefined activity metabolic equivalent task (MET) as determined by the activity monitor) included average time/day spent in light, moderate or higher intensity (≥3 METs) activity and number of steps/day. We also reported physical activity levels for age-appropriate MET levels according to

![Figure 1](image-url). Study design. V1–V9 Study Visit 1 to 9. V1 and V2 were scheduled 4 and 3 weeks prior to randomisation. HH, HandiHaler.

| Table 1. Patient inclusion and exclusion criteria |
|-----------------------------------------------|
| **Inclusion criteria**                        | **Exclusion criteria**                        |
| • Male or female                              | • Prior maintenance medication (LABAs, inhaled or systemic corticosteroids, theophylline, leukotriene receptor antagonists) within six months prior to screening |
| • Age 40–80 years                             | • Current chronic treatment with systemic steroids |
| • Smoking history ≥ 10 pack-years             | • Diagnosis of asthma                          |
| • Diagnosis of COPD (GOLD stage II): post-bronchodilator FEV1/FVC ratio < 0.7; FEV1 ≥ 50 and < 80% of predicted normal; MRC dyspnoea score ≥ 2 | • History of cystic fibrosis                     |
| • Ability to: demonstrate compliance with HandiHaler, a salbutamol MDI, and the activity monitor; perform acceptable PFTs; an exercise stress test; follow study procedures | • Upper and/or lower respiratory tract infection or COPD exacerbation in six weeks prior to, or during, screening |

Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; LABA, long-acting β2-agonist; MDI, metered-dose inhaler; MRC, Medical Research Council; PFTs, pulmonary function tests.
to Haskell and Pollock (for subjects aged 40–64 years, light intense activity is 2.5–4.4 METs and moderate intense activity is 4.5–5.9 METs; for subjects aged 65–79 years, the levels are 2.0–3.5 and 3.6–4.7 METs, respectively). Physicist’s global assessment reflected the physician’s opinion of the patient’s overall clinical condition (based on need for concomitant medication, number and severity of exacerbations since last visit, cough and dyspnoea severity, and ability to exercise). The patient’s global assessment reflected the patient’s opinion of their own overall condition. Both assessments occurred at weeks 0, 12 and 24.

The Work Productivity and Activity Impairment (WPAI) questionnaire was administered at baseline and at all subsequent visits. The WPAI is a six-item self-administered instrument that is novel in COPD research and is easy to complete by patients.

Statistical analysis
All efficacy analyses, except physical activity endpoints, were performed using the full analysis set population (all randomised patients receiving ≥ 1 dose of study drug, with FEV1 at baseline and ≥ 1 measurement after baseline). Missing data from early withdrawal due to worsening COPD were replaced by the least favourable prior observation. Other missing values were replaced by the corresponding time point at the most recent non-missing visit. Details about these analyses and calculation of sample size are contained in the Supplementary Materials and Methods.

Physical activity endpoints were assessed using the activity evaluable set, defined as all full analysis set patients with physical activity data available for ≥ 12 weeks.

Continuous data were summarised as means ± s.d. or as geometric mean and corresponding 95% confidence interval (CI); categorical data were summarised as counts and percentages. Continuous efficacy endpoints (change from baseline) were assessed using an analysis of covariance model with terms for treatment group, investigator site and baseline value. Analysis of categorical endpoints was performed using Cochran–Mantel–Haenszel tests with investigator site as the stratification variable. All hypotheses were tested using a type I error rate of 0.05 and statistical tests were two-sided.

WPAI scores were analysed by analysis of covariance models, with terms for treatment group, investigator site and baseline value. No data imputation was performed for missing patient-reported outcome (PRO) values.

RESULTS
Patient disposition
The trial was conducted between April 2007 and July 2010 and included 457 randomised patients (238 tiotropium, 219 placebo; Figure 2). The baseline characteristics and demographics of the patients in the two groups were generally comparable (Table 2). The mean age was 62 years, 68% were men and mean post-bronchodilator FEV1 was 1.93 l (66% predicted). Use of prior and concomitant drug treatments was generally balanced between the groups. Of the 48 patients who discontinued (27 in the tiotropium group, 21 in the placebo group, not significant; Figure 2), only 15 met the inclusion criteria for the activity evaluable set and were included in the activity analysis set population (eight receiving tiotropium, seven receiving placebo). Discontinued patients in both groups were much less active at baseline (by number of steps, age-appropriate light, moderate or higher activity and moderate or higher activity (≥ 3 METs)) than those who completed the study. Mean duration of wearing the activity monitor was comparable between those who completed the study and those who discontinued (mean 17.1 vs. 16.8 h; P = 0.771). Baseline co-morbidities by system organ class are presented in Table 3.

The WPAI score for activity impairment due to health at baseline was similar in the tiotropium and placebo groups (28 ± 22 and 25 ± 21%, respectively). Altogether, 41% of patients in the tiotropium group and 37% in the placebo group were employed; there was no difference in the degree of impairment while working. The percentage of work time missed due to ill health at baseline was low (tiotropium group 2.7 ± 12%; placebo group 5.5 ± 19%).

Lung function
Figure 3a shows the mean pre-dose FEV1 (raw values in litres) at time 0 and the mean post-dose FEV1 for up to 3 h post-dose in the tiotropium and placebo groups at baseline and the last visit (week 24). For the primary endpoint of mean change from baseline in FEV1 AUC0–3h at week 24, tiotropium was superior to placebo (0.19 ± 0.27 l vs. −0.03 ± 0.22 l; least-squares (LS) mean difference 0.23 l; 95% CI, 0.18–0.27; P < 0.001; Figure 3b. The corresponding mean change from baseline to week 24 values for FVC AUC0–3h were 0.23 ± 0.47 l for tiotropium and −0.06 ± 0.37 l for placebo (LS mean difference tiotropium versus placebo 0.31 l; 95% CI, 0.24–0.38; P < 0.001; Figure 3c).

Figure 3d presents trough FEV1 at all visits in both groups. After 24 weeks, the mean change from baseline in trough FEV1 favoured tiotropium (0.08 ± 0.27 vs. −0.05 ± 0.22 l with placebo; LS mean...
difference 0.14 l; 95% CI, 0.09–0.18; P < 0.001). Similarly, mean trough FVC at week 24 was higher with tiotropium than with placebo (0.10 ± 0.42 vs. –0.10 ± 0.37 l; LS mean difference 0.21 l; 95% CI, 0.14–0.28; P < 0.001; Figure 3e).

At week 24 the mean increase from baseline in peak FEV1 was significantly higher with tiotropium than with placebo (0.28 ± 0.27 vs. 0.04 ± 0.23 l; LS mean difference 0.24 l; 95% CI, 0.19–0.29; P < 0.001). The mean change from baseline in peak FVC was also higher with tiotropium than with placebo (0.41 ± 0.59 vs. 0.08 ± 0.38 l; LS mean difference 0.33 l; 95% CI, 0.24–0.42; P < 0.001).

Physical activity

Figure 4 summarises the overall changes in physical activity levels from baseline in both treatment groups (moderate or higher intensity activity/day (using age-appropriate METs) and mean number of steps/day). While physical activity levels were higher numerically in the tiotropium group than in the placebo group, they were not statistically significantly different between groups at any time point. From baseline to week 24, the mean number of minutes/day in light activity increased slightly in the tiotropium and placebo groups (baseline means 102.6 ± 74.13 and 98.7 ± 73.23 min; week 24 means 111.4 ± 81.71 min and 101.4 ± 79.85 min, respectively). The proportion of patients classified as inactive (<6,000 steps/day) was lower with tiotropium than with placebo (significant at week 12) (see Supplementary Table S1). While similar trends were observed at all other visits, the differences did not reach statistical significance.

Global health assessments and WPAI scores

At baseline, 58.1 and 58.9% of patients in the two groups received a physician’s global assessment of ‘good’ (Table 4); patients in the tiotropium group were classified as ‘excellent’ less frequently than in the placebo group (7.5 vs. 11.1%). However, at week 24, patients treated with tiotropium were more frequently classified by their physician as ‘excellent’ than those in the placebo group (18.1 vs. 10.9%) and were less frequently classified as ‘poor/fair’ compared with the placebo group (19.0 vs. 25.4%), signifying improved health status with tiotropium compared with placebo (P = 0.045 at week 24). The trends were similar for the patient’s global assessment (Table 4); however, the between-group difference was significant only at week 12 in favour of tiotropium (P = 0.01).

After 24 weeks the baseline WPAI score improved by −2.1% ± 22% in the tiotropium group but deteriorated by 5.6% ± 20% in the placebo group (LS mean difference for tiotropium versus placebo −3.76 l; 95% CI, −7.39 to −0.13; P = 0.043); patients receiving tiotropium also tended to experience less impairment while working than those in the placebo group (LS mean difference −5.88%; 95% CI, −12.1 to 0.35; P = 0.064). The percentage of work time missed due to ill health at week 24 was not significantly different between the two groups (LS mean difference for

### Table 2. Patient baseline characteristics

| Characteristic                  | Tiotropium (n = 238) | Placebo (n = 219) |
|--------------------------------|----------------------|-------------------|
| Age, years                     | 61.2 ± 8.2           | 62.3 ± 8.6        |
| Male, %                        | 69.7                 | 67.1              |
| Height, cm                     | 171.4 ± 8.2          | 170.5 ± 8.3       |
| Weight, kg                     | 79.7 ± 16.6          | 83.2 ± 20.1       |
| BMI, kg/m²                     | 27.0 ± 4.9           | 28.5 ± 5.9        |
| Current smoker, %              | 61.7                 | 57.0              |
| Smoking history, pack-years    | 44.0 ± 22.4          | 43.9 ± 34.9       |

**Pre-bronchodilator**

| FEV1, l                        | 1.75 ± 0.44          | 1.70 ± 0.44       |
| FVC, l                         | 3.25 ± 0.79          | 3.17 ± 0.84       |

**Post-bronchodilator**

| FEV1, l                        | 1.95 ± 0.44          | 1.90 ± 0.43       |
| FEV1, % predicted              | 65.6 ± 8.2           | 65.8 ± 8.2        |
| FVC, l                         | 3.53 ± 0.80          | 3.41 ± 0.87       |
| FEV1/FVC                       | 0.6 ± 0.1            | 0.6 ± 0.1         |

**WPAI**

| Activity impairment due to health, %a | 28.0 ± 22.3          | 25.4 ± 21.4       |
| Patients employed, %                | 41                   | 37                |
| Impairment while working due to health, %b | 21.1 ± 21.1          | 17.2 ± 20.2       |

**Activity**

| Steps, number/day               | 6,748.7              | 6,374.5 (5,889.2–6,899.9) |
| Time in moderate or higher (≥3 METs), min/day | 86.8                 | 77.2 (67.9–87.7)       |
| Time in age-appropriate moderate or higher activity, min/day | 24.7                 | 20.6 (16.85–25.22)    |

Data are mean ± s.d. unless specified otherwise. Abbreviations: BMI, body mass index; CI, confidence interval; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GM, geometric mean; METs, metabolic equivalents; WPAI, Work Productivity and Activity Impairment questionnaire with outcomes expressed as impairment percentages (higher numbers indicate greater impairment and less productivity; i.e., worse outcomes).

a n = 433.
b n = 164.
c Median values.
tiotropium versus placebo –2.33%; 95% CI, −7.39 to 2.73; \( P = 0.363 \).

Safety

Overall, AEs were infrequent for both groups and most were not considered treatment related (Table 5). Few patients experienced exacerbations recorded as AEs, and the incidence was lower in the tiotropium group than in the placebo group (odds ratio 0.42; 95% CI, 0.21–0.84). There was also a lower incidence of cough, bronchitis, and dyspnoea in the tiotropium group. No SAEs were considered related to study drug (see Supplementary Table S2), and patients recovered from all events. There were no deaths.

**DISCUSSION**

Main findings

Our results provide insight into the long-term effects of tiotropium in patients with moderate COPD who are naive to respiratory maintenance therapy. The main finding is that the primary endpoint was met, with tiotropium plus p.r.n. salbutamol significantly improving the FEV₁, AUC₀–₃h post-dose response in synchrony with other lung function improvements after 24 weeks. Additionally, tiotropium had a positive impact on secondary endpoints relevant to COPD patients. The study also suggested that optimising pharmacotherapy may improve aspects of physical activity, but the results are inconclusive. Tiotropium was well tolerated and safety was consistent with previous data.⁴,⁷

Strengths and limitations of this study

This study has a number of unique characteristics. First, it targeted a patient population with moderate COPD receiving first maintenance respiratory therapy or matching placebo. Unlike other trials, the patients represented the entire range of GOLD stage II COPD (post-bronchodilator FEV₁ ≥ 50 to < 80% predicted; FEV₁ was 300–350 ml, approximately 7% predicted larger than for GOLD stage II patients recruited in the UPLIFT and TORCH trials.⁴,⁹ Moreover, many patients (39%) were employed and most were still engaged in physical activity, with baseline levels corresponding to those of other GOLD stage II patient cohorts.¹⁵,²⁵ This suggests that the study population represents the milder end of the GOLD stage II disease spectrum, making it particularly interesting for clinicians. Dyspnoea was measured only during the screening period using the Medical Research Council dyspnoea scale, not baseline dyspnoea index. The Clinical COPD Questionnaire and the Chronic Respiratory Disease Questionnaire were completed only at baseline for phenotyping and therefore could not be used as an outcome measure in the present trial. The effects of tiotropium on health-related quality of life in patients comparable to those in the present trial, however, is available in a sub-analysis of the UPLIFT trial¹⁰ and was not attempted to be replicated in the present study.

When this study was designed (in 2006/7), physical activity monitoring was in its infancy. We therefore did not include physical activity as a primary endpoint. Today there is more clarity on factors affecting the outcome of such monitoring, number of days of assessment needed, hours/day and validity of activity monitors in COPD.²⁶–²⁸ We measured physical activity using a validated activity monitor²⁰,²⁷ as an exploratory endpoint, which allowed for some flexibility in the analysis. Although lung function was improved with tiotropium, this was not readily translated into enhanced physical activity as between-group differences were numerically small and non-significant. This was true despite using individualised activity plans and motivational interviewing techniques (monthly, 20 min, face-to-face consultations).¹⁷ These interventions may have been insufficient to increase physical activity levels notably in the studied time frame and more frequent motivational sessions, proper pulmonary rehabilitation,²⁹ or selection of inactive patients at baseline may have been more successful. Physical activity levels can also be influenced by other factors such as climate, personality traits and co-morbidities, social environment and regional policy;³⁰ determining these influences poses a methodological challenge. Nevertheless, integration of activity interventions into routine consultation in pulmonary clinics or even primary care settings may achieve meaningful results. Our study surely calls for better understanding and assessment of physical activity. The ‘Physical Activity as a Crucial Patient Reported Outcome in COPD (PROactive)’ IMI-JU project aims to do so. It will develop and validate a PRO tool to investigate dimensions of physical activity that are considered essential by patients. Such instruments should help us to understand better the benefits of interventions in enhancing physical activity from a patient perspective.

Interpretation of findings in relation to previously published work

To date, only one study has prospectively verified the benefit of tiotropium in patients with moderate COPD not treated with other maintenance pharmacotherapy.³¹ However, this was relatively short term (3 months). The absolute difference in trough FEV₁ volumes between tiotropium and placebo in the current study is comparable to the maintenance therapy–naïve cohort in the UPLIFT trial at 6 months (123 ml)¹⁰ and patients with mild disease (FEV₁ 73% predicted) in a Swedish study (118 ml) after 3 months.³¹ Our study is the first prospective multicentre 6 month trial to use physical activity as an outcome measure in maintenance

---

**Table 3.** Concomitant diagnoses at baseline by system organ class

| MedDRA preferred term                                      | Tiotropium | Placebo |
|------------------------------------------------------------|------------|---------|
| **Medical history**                                         |            |         |
| Number of patients                                         | 238 (100)  | 219 (100) |
| Number of patients with ≥ 1 disease or syndrome            | 190 (79.8) | 179 (81.7) |
| Blood and lymphatic system disorders                       | 0 (0.0)    | 0 (0.0) |
| Cardiac disorders                                          | 30 (12.6)  | 24 (11.0) |
| Congenital, familial and genetic disorders                 | 0 (0.0)    | 1 (0.5)  |
| Ear and labyrinth disorders                                | 2 (0.8)    | 9 (4.1)  |
| Endocrine disorders                                        | 16 (6.7)   | 13 (5.9) |
| Eye disorders                                               | 12 (5.0)   | 12 (5.5) |
| Gastrointestinal disorders                                 | 41 (17.2)  | 43 (19.6) |
| General disorders and administration site conditions       | 1 (0.4)    | 2 (0.9)  |
| Hepatobiliary disorders                                    | 5 (2.1)    | 1 (0.5)  |
| Immune system disorders                                    | 22 (9.2)   | 17 (7.8) |
| Infections and infestations                                 | 4 (1.7)    | 7 (3.2)  |
| Injury poisoning and procedural complications               | 1 (0.4)    | 4 (1.8)  |
| Investigations                                             | 4 (1.7)    | 5 (2.3)  |
| Metabolism and nutritional disorders                       | 69 (29.0)  | 86 (39.3) |
| Musculoskeletal and connective tissue disorders             | 72 (30.3)  | 64 (29.2) |
| Neoplasms, benign, malignant, unspecified                  | 0 (0.0)    | 0 (0.0)  |
| Nervous system disorders                                    | 23 (9.7)   | 28 (12.8) |
| Psychiatric disorders                                      | 32 (13.4)  | 22 (10.0) |
| Renal and urinary disorders                                 | 6 (2.5)    | 10 (4.6) |
| Reproductive system and breast disorders                   | 18 (7.6)   | 20 (9.1) |
| Respiratory, thoracic and mediastinal disorders            | 16 (6.7)   | 8 (3.7)  |
| Skin and subcutaneous tissue disorders                     | 11 (4.6)   | 11 (5.0) |
| Social circumstances                                       | 3 (1.3)    | 3 (1.4)  |
| Surgical and medical procedures                            | 6 (2.5)    | 3 (1.4)  |
| Vascular disorders                                         | 105 (44.1) | 118 (53.9) |

Data shown as number (%) of patients.
Therapy–naïve patients with COPD. In the maintenance therapy–naïve cohort in the UPLIFT trial, patients receiving tiotropium showed a slower decline in the activity domain of the St George’s Respiratory Questionnaire, suggesting that patients receiving bronchodilators may be less likely to become inactive. Supporting this, there were numerically more active patients (>6,000 steps/day) in the tiotropium group compared with placebo in the present study. However, further exploration of the impact of first-time maintenance therapy on physical activity levels is needed.

Figure 3. Lung function outcomes (presented as means ± s.e.) (a) Pre-dose FEV₁ (raw values in litres) at time − 10 min and post-dose FEV₁ at 30, 60, 90, 120, 150 and 180 min, by treatment group at baseline and last study visit, (b) FEV₁ AUC₀–₃h, (c) FVC AUC₀–₃h, (d) trough FEV₁, and (e) trough FVC by treatment group during the course of the study. AUC₀–₃h, area under the curve between 0 and 3 h; CI, confidence interval; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; LS, least squares.

Figure 4. Overall physical activity levels (using age-appropriate metabolic equivalents) as shown by (a) mean min/day in moderate- or higher-intensity physical activity and (b) mean number of steps per day in the tiotropium group (solid line) and the placebo group (dashed line).
Table 4. Physician and patient global assessments of overall health status

| Tiotropium | Placebo | P value |
|------------|---------|---------|
| **Physician’s assessment** | **Week 24** | **Week 24** |
| Poor/fair | 78 (34.4%) | 41 (19.0%) | 62 (30.0%) | 51 (25.4%) | 0.045 |
| Good | 132 (58.1%) | 136 (63.0%) | 122 (58.9%) | 128 (63.7%) |
| Excellent | 17 (7.5%) | 39 (18.1%) | 23 (11.1%) | 22 (10.9%) |

| **Patient’s self-assessment** | **Week 24** | **Week 24** |
| Poor/fair | 95 (41.9%) | 56 (25.9%) | 72 (35.0%) | 66 (32.8%) |
| Good | 117 (51.5%) | 128 (59.3%) | 111 (53.9%) | 116 (57.7%) |
| Excellent | 15 (6.6%) | 32 (14.8%) | 23 (11.2%) | 19 (9.5%) |

Patients and physicians could judge the overall health status as poor, fair, good, or excellent. ‘Poor’ and ‘fair’ were pooled. Data are prevalence of the scores with percentages in parentheses.

$P$ values relate to the outcome of the chi-square test.

Table 5. Incidence of treatment-emergent AEs (all causality and treatment related; ≥1% in either treatment group) by decreasing cumulative frequency

| MedDRA preferred term | All causality | Treatment related$^a$ |
|-----------------------|---------------|----------------------|
| **Tiotropium** | **Placebo** | **Tiotropium** | **Placebo** |
| Evaluation for AEs | 238 (100) | 219 (100) | 238 (100) | 219 (100) |
| COPD (i.e., an exacerbation)$^b$ | 11 (4.6) | 24 (11.0) | 0 | 2 (0.9) |
| Nasopharyngitis | 16 (6.7) | 11 (5.0) | 0 | 0 |
| Upper RTI | 7 (2.9) | 5 (2.3) | 0 | 1 (0.5) |
| Cough | 4 (1.7) | 8 (3.7) | 1 (0.4) | 3 (1.4) |
| Bronchitis | 2 (0.8) | 8 (3.7) | 0 | 2 (0.9) |
| Diarrhoea | 6 (2.5) | 3 (1.4) | 0 | 0 |
| Headache | 2 (0.8) | 5 (2.3) | 1 (0.4) | 1 (0.5) |
| Influenza | 4 (1.7) | 2 (0.9) | 0 | 0 |
| RTI | 3 (1.3) | 3 (1.4) | 0 | 0 |
| Rhinitis | 2 (0.8) | 4 (1.8) | 0 | 0 |
| Dry mouth | 3 (1.3) | 2 (0.9) | 3 (1.3) | 1 (0.5) |
| Viral RTI | 3 (1.3) | 2 (0.9) | 0 | 0 |
| Hypertension | 3 (1.3) | 2 (0.9) | 1 (0.4) | 0 |
| Arthralgia | 2 (0.8) | 3 (1.4) | 0 | 0 |
| Dyspnœa | 0 | 5 (2.3) | 0 | 0 |
| Nausea | 3 (1.3) | 1 (0.5) | 0 | 0 |
| Herpes zoster | 3 (1.3) | 1 (0.5) | 0 | 0 |
| Chronic bronchitis | 1 (0.4) | 3 (1.4) | 0 | 0 |
| Back pain | 0 | 4 (1.8) | 0 | 0 |
| Hyperglycaemia | 0 | 3 (1.4) | 0 | 1 (0.5) |
| Epistaxis | 0 | 3 (1.4) | 0 | 2 (0.9) |

Data shown as number (%). Patients and physicians could judge the overall health status as poor, fair, good, or excellent. ‘Poor’ and ‘fair’ were pooled. Data are prevalence of the scores with percentages in parentheses.

$P$ values relate to the outcome of the chi-square test.

**Table 4**

**Table 5**

Implications for future research, policy and practice

In previous trials studying bronchodilator therapy in moderate COPD, health-related quality of life was the only patient-centred outcome to be analysed. The present study investigated the effect of tiotropium on global health status and impairment of worker productivity. Physicians assessed the general health status of tiotropium-treated patients as better than with placebo. Similarly, patients treated with tiotropium rated their own status as ‘excellent’ more frequently than those receiving placebo. More specific assessment is justified in using validated PRO tools in maintenance-naive patients. Discrete benefits in favour of tiotropium were also demonstrated by the WPAI, suggesting that treatment with a long-acting bronchodilator may reduce work-related activity impairment in COPD patients, although the clinical significance of changes in WPAI score is unknown. How improvements on the WPAI may translate into health economic gains should also be evaluated in future larger scale trials in younger and professionally active COPD patients.

**Conclusions**

This study demonstrates that tiotropium enhanced lung function and had a positive impact on PROs in individuals with GOLD stage II COPD disease naive to maintenance therapy. Tiotropium also reduced COPD symptoms and exacerbations (reported as AEs), supporting the initiation of maintenance therapy earlier in the COPD disease process.

**ACKNOWLEDGEMENTS**

Editorial support was provided by Yamin Ikhawdikar, PhD and Godfrey Lisk, PhD at PAREXEL MMS.

**CONTRIBUTIONS**

All authors were involved in trial design, monitoring of study conduct, approval of statistical analyses, data interpretation and review, writing and decisions regarding publication of the manuscript. All authors had full access to the data and vouch for the accuracy and completeness of the data and analyses.

**COMPETING INTERESTS**

TT has received fees as chair of the steering committee from Pfizer, consultancy fees from AstraZeneca and lecture fees from Boehringer Ingelheim, Chiesi and Novartis. FCS has received grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, Forest Pharmaceuticals, Actelion, AstraZeneca, NIH and fees for advisory boards from GlaxoSmithKline, AstraZeneca and PneumRx. MD has received fees for advisory boards from Boehringer Ingelheim, GlaxoSmithKline, Nycomed and Altana, consultancy and lectures fees from Boehringer Ingelheim and GlaxoSmithKline, and grants from AstraZeneca. NMS has received consultancy fees from Novartis, Elpen, AstraZeneca and Pfizer, grants from GlaxoSmithKline and Takeda, and lecture fees from Novartis, Elpen, AstraZeneca and Pfizer. CY is an employee of Pfizer and a shareholder. SK, SCS and IMW were
employees of Pfizer at the time of the study but are now currently employed by Novartis Pharmaceuticals, East Hanover, NJ, USA.

**FUNDING**

The study was funded by Pfizer Inc and Boehringer Ingelheim Pharma GmbH & Co KG.

**REFERENCES**

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD. http://www.goldcopd.org/, 2013.
2. Adams SG, Anzueto A, Briggs DD Jr, Menjoge SS, Kesten S. Tiotropium in COPD patients not previously receiving maintenance respiratory medications. Respir Med 2006; 100: 1495–1503.
3. Kornmann O, Beeh KM, Beier J, Geis UP, Koell M, Buhl R. Newly diagnosed chronic obstructive pulmonary disease. Clinical features and distribution of the novel stages of the Global Initiative for Obstructive Lung Disease. Respiration 2003; 70: 67–75.
4. Tashkin DP, Celli B, Senn S, Burkhardt D, Kesten S, Menjoge S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543–1554.
5. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317–326.
6. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L et al. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur Respir J 2002; 19: 209–216.
7. Decramer M, Celli B, Kesten S, Lystig T, Mehras S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171–1178.
8. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332–338.
9. Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
10. Troosters T, Celli B, Lystig T, Kesten S, Mehras S, Tashkin DP et al. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial. Eur Respir J 2010; 36: 65–73.
11. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Scirurba FC, Richter K et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168–1178.
12. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809–817.
13. O'Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguainlia B et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–840.
14. Nieminen M, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA et al. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J 2012; 40: 1115–1122.
15. Troosters T, Scirurba F, Battaglia S, Langer D, Valluri SR, Martino L et al. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir Med 2010; 104: 1005–1011.

16. Watz H, Waschki B, Boehrme C, Claussen M, Meyer T, Magnussen H. Extra-pulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med 2008; 177: 743–751.
17. Troosters T, Weisman I, Dobbelis F, Giardino N, Valluri SR. Assessing the impact of tiotropium on lung function and physical activity in GOLD stage II COPD patients who are naive to maintenance respiratory therapy: a study protocol. Open Respir Med J 2011; 5: 1–9.
18. International Conference on Harmonisation. Good clinical practice guidelines. http://www.ich.org/products/guidelines/. Accessed June 2013.
19. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338.
20. Rabinovich RA, Louvaris Z, Raste Y, Langer D, Van Remoortel H, Giavedoni S et al. Validity of physical activity monitors during daily life in patients with COPD. Eur Respir J 2013; 42: 1205–1215.
21. National Center for Chronic Disease Prevention and Health Promotion. Physical Activity and Health: A Report of the Surgeon General. Chapter 2: Historical Background, Terminology, Evaluation of Recommendations and Measurement, 2011. http://www.cdc.gov/nccdphp/si/chap2.htm.
22. Bailey WC, Scirurba FC, Hanania NA, Donohue JF, Ferguson GT, Zibjak JD et al. Development and validation of the Chronic Obstructive Pulmonary Disease Assessment Questionnaire (COPD-AQ). Prim Care Respir J 2009; 18: 198–207.
23. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353–365.
24. Stahl E, Jansson SA, Jonsson AC, Svenseson K, Lundback B, Andersson F. Health-related quality of life, utility, and productivity outcomes instruments: ease of completion by subjects with COPD. Health Qual Life Outcomes 2003; 1: 18.
25. Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with COPD. Eur Respir J 2009; 33: 262–272.
26. Troosters T, Van Der Molen T, Polkey MI, Rabinovich RA, Vogiatzis I, Weisman I et al. Improving physical activity in COPD: towards a new paradigm. Respir Res 2013; 14: 1–8.
27. Van Remoortel H, Raste Y, Louvaris Z, Giavedoni S, Burtin C, Langer D et al. Validity of six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect calorimetry. PLoS One 2012; 7: e39198.
28. Van Remoortel H, Giavedoni S, Raste Y, Burtin C, Louvaris Z, Gimeno-Santos E et al. Validity of activity monitors in health and chronic disease: a systematic review. Int J Behav Nutr Phys Act 2012; 9: 84.
29. Troosters T, Gosselink R, Janssens W, Decramer M. Exercise training and pulmonary rehabilitation: new insights and remaining challenges. Eur Respir Rev 2010; 19: 24–29.
30. Bauman AE, Reis RS, Sallis JF, Wells J, Loos RJ, Martin BW. Correlates of physical activity: why are some people physically active and others not? Lancet 2012; 380: 258–271.
31. Johansson G, Lindberg A, Romberg K, Nordstrom L, Gerken F, Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim Care Respir J 2008; 17: 169–175.
32. Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011; 11: 612.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

Supplementary Information accompanies the paper on the npj Primary Care Respiratory Medicine website (http://www.nature.com/npjpcrm)